CAJ | 학술논문

胃肠间质瘤(gastrointestinal stromal tumor,GIST)是最常见的胃肠道间叶源性肿瘤.经过近十余年的发展,GIST的治疗形成了以外科手术联合靶向药物的治疗模式.伊马替尼(imatinib mesylate,IM)作为GIST患者术后辅助治疗的一线药物,其应用显著减少了GIST患者的术后复发转移,延长了患者生存.对大多数高危风险GIST患者来说,目前SSGXVⅢ/AIO研究推荐伊马替尼术后辅助治疗至少应用3年.然而最佳的辅助治疗持续时间和随访方案尚未明确,仍处于边治疗边总结中,也期待能提出一指导个体化治疗的评估标准.
위장간질류(gastrointestinal stromal tumor,GIST)시최상견적위장도간협원성종류.경과근십여년적발전,GIST적치료형성료이외과수술연합파향약물적치료모식.이마체니(imatinib mesylate,IM)작위GIST환자술후보조치료적일선약물,기응용현저감소료GIST환자적술후복발전이,연장료환자생존.대대다수고위풍험GIST환자래설,목전SSGXVⅢ/AIO연구추천이마체니술후보조치료지소응용3년.연이최가적보조치료지속시간화수방방안상미명학,잉처우변치료변총결중,야기대능제출일지도개체화치료적평고표준.
Gastrointestinal stromal tumor (GIST) represents the most common mesenchymal tumor of the gastrointestinal tract.With decades of development,surgical excision combined with molecular targeted agents is becoming the mode for the GIST treatment.Imatinib mesylate (IM) is the first-line therapy medicine for GIST adjuvant treatment,and it significantly reduces recurrence or metastasis and increases survival.According to the recently results of SSGXV Ⅲ/AIOstudy,imatinib adjuvant therapy should be administered for at least 3 years for the GIST patients with a high estimated risk of recurrence and metastasis after surgery.Nevertheless,the optimal duration of the adjuvant therapy or the follow-up policy remains unclear,and we look forward to standard assessment criteria for individualized treatment.